China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Urgent Approval Warranted, Researchers Say
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
You may also be interested in...
Long-term safety results from the mRNA COVID-19 vaccine’s Phase II trial in a Chinese population could pave the way for its approval in China, investigators say.
China is signalling its intention to gradually re-open its borders amid real-world data showing few mild-to-moderate cases progress to severe symptoms. Meanwhile, Pfizer's Paxlovid is seemingly struggling to gain traction amid use guideline changes.
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.